APA (7th ed.) Citation

AM, M., ME, D., G, L., E, M., AA, M., AI, M., . . . K, K. (2023). Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: A multi-institutional phase I trial. Nature communications, 14(1), 5332. https://doi.org/10.1038/s41467-023-40813-w

Chicago Style (17th ed.) Citation

AM, Monjazeb, et al. "Atezolizumab Plus Stereotactic Ablative Radiotherapy for Medically Inoperable Patients with Early-stage Non-small Cell Lung Cancer: A Multi-institutional Phase I Trial." Nature Communications 14, no. 1 (2023): 5332. https://doi.org/10.1038/s41467-023-40813-w.

MLA (9th ed.) Citation

AM, Monjazeb, et al. "Atezolizumab Plus Stereotactic Ablative Radiotherapy for Medically Inoperable Patients with Early-stage Non-small Cell Lung Cancer: A Multi-institutional Phase I Trial." Nature Communications, vol. 14, no. 1, 2023, p. 5332, https://doi.org/10.1038/s41467-023-40813-w.